News

Mainz, May 15-17, 2018 – CIMT 2018 Annual Meeting We are excited about the upcoming Annual Meeting of the Association for Cancer Immunotherapy (CIMT) in our hometown Mainz. Our scientists will be presenting their research in several sessions and look forward to discussing their projects. Thursday, 17 May 2018, Short Talk Session IV Therapeutic Vaccination

Mainz, Germany, April 18, 2018 – Ugur Sahin, Scientific Director at TRON, has been awarded one of the prestigious ERC Advanced Grants 2017 for his project ‘SUMMIT – Stepping Up mRNA Mutanome Immunotherapy’, totaling 2.5 Million Euros over 5 years. The ERC Advanced Grants are awarded to well-established, leading principal investigators to pursue ground-breaking projects. SUMMIT is one

Insight into the human HLA expression pattern opens up new ways of improving cancer vaccine development The human leukocyte antigen system (HLA system) is a group of genes that are central to the function of the immune system. These protein complexes can be found either on almost all cells (HLA class I complex) or on

Mainz, March 23, 2018 – TRON is delighted to announce a review authored by Ugur Sahin and Özlem Türeci in the journal Science. “Personalized vaccines for cancer immunotherapy” outlines the genetic basis for why almost every cancer is unique, and how with innovations in mutation mapping, target validation and vaccine production, it is possible to

Mainz, March 2018 – On March 15th, Prof. Dietmar Zehn from the Technical University of Munich, School of Life Sciences Weihenstephan, will be visiting Mainz in the context of our Seminars in Translational Oncology series (SITO). You are cordially invited to his talk at 5 pm in building 708 of the University Medicine Mainz. The

Mainz, February 16, 2018 – The Keystone Symposium on Antibodies as Drugs: Translating Molecules into Treatments, will take place February 25th – March 1st, 2018 at the Whistler Conference Centre in Whistler, Canada. Ugur Sahin will speak in the session on Novel Ways to Deliver Antibody Therapy on Thursday, March 1.  The title of his lecture

We are pleased to announce a three-year grant from the Falconwood Foundation, New York, USA, totalling 3 Million Euros. The grant supports the launch of a new research project to identify biomarkers specific for neuroendocrine tumors (NETs) that are crucial for the development of new, personalized immunotherapies to treat NET patients. Further details are announced

TRON has been shortlisted for Cancer Research UK’s Grand  Challenge Award as part of team BLUEPRINT   TRON is part of a multi-disciplinary team of scientists that has been shortlisted to the final stages of Cancer Research UK’s Grand Challenge*. The team is led by Dr. Lindy Durrant from the University of Nottingham and includes

Mainz, January 23, 2018 – The Keystone Symposium on Lymphocytes and their Role in Cancer will take place February 11th-15th 2018 at the Keystone Resort in Keystone, Colorado.  This is a joint event with Emerging Cellular Therapies: T Cells and Beyond. Ugur Sahin will chair the session on Cellular Therapies in Blood Malignancies,  and give a

The concept of delivering genetic material to defective cells to treat diseases or to vaccinate healthy people against infections has been around for quite some time. Nevertheless, key challenges remain, such as efficient delivery of the material as well as duration of gene expression.

In the course of evolution, the immune system has developed sophisticated mechanisms to identify and eliminate invading pathogens and degenerate cells, thereby preventing infection and tumor occurrence.  When these mechanisms are ineffective or somehow bypassed, tumors or chronic infections may form. Clarifying the processes leading to ineffective immune defense is the central goal of the

The Antibody Engineering and Therapeutics conference will take place December 11th-15th 2017 at the Manchester Grand Hyatt in San Diego, California.

The Berlin Institute of Health, together with the Charité Universitätsmedizin Berlin, Max Delbrück Center for Molecule Medicine and Tagesspiegel, will host the second Future Medicine: Innovation in Health Science meeting on 7th November.

Mainz, 2017-10-25 – TRON scientific advisor Prof. Dr. Dr. Cornelis J. Melief, Leiden, Netherlands, will be awarded with the degree of an honorary medical doctor. Melief will be awarded for his lifetime achievements as a pioneer of tumor immunology, as well as for his commitment and deserts regarding immunological research in Mainz. Further information about

The topic of this year’s EFIS-EJI Ruggero-Ceppellini Advanced School of Immunology is “Tumour Immunology: from tissue microenvironment to immunotherapy.”

The National Cancer Institute’s Center of Excellence in Immunogy sponsors a two-day symposium with the theme “Cancer Immunology and Immunotherapy: From Conception to Delivery”.

The Institute for Molecular Life Sciences at Radboud University Medical Center (RIMLS) will host a mini-symposium entitled “Chemical Immunology”. 

The 1st Crick International Cancer Conference will bring together leading cancer scientists from all over the world to discuss the latest findings in cancer metabolism, the tumor microenvironment, and how the cancer genotype changes over time.

Mainz, September 23, 2017 – The Annual Meeting of the Leopoldina National Academy of Sciences will be held on 22 and 23 September in Halle (Saale).

Mainz, September 21, 2017 – The working group Dermatological Oncology (ADO) organizes from 21-23 September the 27th German Skin Cancer Congress in the Rheingoldhalle Mainz.

Among nucleic acid-based delivery platforms, self-amplifying RNA (saRNA) vectors are of increasing interest for applications such as transient expression of recombinant proteins and vaccination. Although saRNA is a promising technology, antigen expression from saRNA is limited by the host cells’ innate interferon response. TRON’s Tim Beissert and colleagues show, in an upcoming issue of Human

Mainz, September 2017 – Am 14. September kommt im Rahmen der Seminarreihe in Translational Oncology (SITO) Prof. Federico Garrido der Universität von Granada Medical School nach Mainz. Sie sind herzlich zu seinem Vortrag um 17.00 Uhr c.t. in Gebäude 708 der Universitätsmedizin Mainz eingeladen.

Mainz, September 6, 2017 – Individualized cancer immunotherapy Prof. Ugur Sahin, Managing Director (Science and Research) and Co-Founder of TRON, will talk at the Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in our hometown Mainz. His talk is titled “Individualized Cancer Immunotherapy – Exploring a new landscape” and will cover the implementation of an RNA-based approach

Mainz, September 2017 – TRON will also participate at the THIRD CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE in Mainz this year. Meet and talk to our experts in: Bioinformatics: Wednesday, 12:30-2:00 pm Next Generation Sequencing: Wednesday, 3:00-4:00 pm Biomarker: Thursday, 11:30-1:00 pm Immunomonitoring: Thursday, 3:00-4:00 pm Pre-Clinical Research: Friday, 12:30-2:00 pm T-cell Vaccines & Immunotherapy: Friday,

Mainz, August 2017 – On Aug. 24th Dr. Evan Newell from the Singapore Immunology Network (SIgN) in Singapore is visiting Mainz in the context of the Seminars in Translational Oncology (SITO).

Mainz, July 5th 2017 – Today, TRON and BioNTech AG announced the publication of Phase I clinical trial results in the renowned journal Nature.

Mainz, June 2017 – We are pleased to announce that our close cooperation partner BioNTech has today published an article in Nature Medicine. The paper entitled “Elimination of large tumors in mice by mRNA-encoded bispecific antibodies” reports preclinical data featuring their novel class of mRNA-encoded antibody drugs called RiboMABs® and describes the application of their

Mainz, June 2017 – On June 10, TRON participated in the charity event „Run for Children®“.

Mainz, June 2017 – Lena Kranz, PhD, has been awarded for her doctoral thesis the 2017 NMFZ prize of the Natural Science and Medical Research Center Mainz (NMFZ), part of the University Medical Center of Mainz.

Mainz, May 2017 – On May 10, 2017, Prof. Dr. Cornelis (Kees) Melief will be honored for life-time achievements in cancer immunotherapy research.